Evofem Biosciences (NASDAQ:EVFM) Share Price Passes Above Fifty Day Moving Average of $0.73
Evofem Biosciences (NASDAQ:EVFM) Share Price Passes Above Fifty Day Moving Average of $0.73
Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) shares passed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.73 and traded as high as $0.76. Evofem Biosciences shares last traded at $0.62, with a volume of 24,934,526 shares.
Wall Street Analyst Weigh In
EVFM has been the topic of a number of research reports. Laidlaw initiated coverage on shares of Evofem Biosciences in a report on Thursday, June 2nd. They issued a "buy" rating and a $3.50 price objective on the stock. Morgan Stanley raised their price objective on shares of Evofem Biosciences from $7.95 to $8.55 and gave the stock an "underweight" rating in a report on Tuesday, April 12th.
Get Evofem Biosciences alerts:Evofem Biosciences Trading Down 22.0 %
The company has a market cap of $7.58 million, a P/E ratio of -0.03 and a beta of -1.51. The business's 50 day simple moving average is $0.73 and its 200 day simple moving average is $3.29.
Evofem Biosciences (NASDAQ:EVFM – Get Rating) last released its earnings results on Tuesday, May 10th. The biotechnology company reported ($2.88) EPS for the quarter, topping analysts' consensus estimates of ($2.99) by $0.11. The firm had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.13 million. Sell-side analysts anticipate that Evofem Biosciences, Inc. will post -2.72 EPS for the current year.Insiders Place Their Bets
In related news, CEO Saundra L. Pelletier acquired 141,000 shares of Evofem Biosciences stock in a transaction dated Friday, May 27th. The shares were purchased at an average price of $0.35 per share, for a total transaction of $49,350.00. Following the completion of the transaction, the chief executive officer now directly owns 236,722 shares in the company, valued at approximately $82,852.70. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.90% of the stock is owned by company insiders.
Institutional Investors Weigh In On Evofem Biosciences
Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp raised its position in shares of Evofem Biosciences by 4.5% during the first quarter. State Street Corp now owns 393,070 shares of the biotechnology company's stock valued at $134,000 after buying an additional 17,021 shares during the last quarter. GSA Capital Partners LLP increased its position in Evofem Biosciences by 1,431.6% in the fourth quarter. GSA Capital Partners LLP now owns 924,781 shares of the biotechnology company's stock worth $347,000 after purchasing an additional 864,400 shares during the last quarter. Finally, Mirador Capital Partners LP increased its position in Evofem Biosciences by 3,408.9% in the first quarter. Mirador Capital Partners LP now owns 2,807,681 shares of the biotechnology company's stock worth $955,000 after purchasing an additional 2,727,664 shares during the last quarter. Institutional investors own 12.92% of the company's stock.
Evofem Biosciences Company Profile
(Get Rating)
Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.
Further Reading
- Get a free copy of the StockNews.com research report on Evofem Biosciences (EVFM)
- Are 3M, Honeywell, GE Buys After Quarterly Reports?
- This Defense Stock Has Bullish Fundamentals AND Technicals
- Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
- CVS and Walgreens Show Why Investment Objectives Matter
- Are Medtronic And Intuitive Surgical Poised For Big Growth?
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
Evofem生物科學公司(納斯達克代碼:EVFM-GET Rating)的股價在週二的交易中超過了50日移動均線。該股的50日移動均線為0.73美元,最高交易價格為0.76美元。Evofem Biosciences的股票最新報0.62美元,成交量為24,934,526股。
華爾街分析師也加入進來
EVFM已經成為許多研究報告的主題。萊德洛在6月2日星期四的一份報告中啟動了對Evofem Biosciences股票的報道。他們對該股的評級為“買入”,目標價為3.5美元。摩根士丹利在4月12日(星期二)的一份報告中將依沃費姆生物科學公司的股票目標價從7.95美元上調至8.55美元,並給予該股“減持”評級。
到達Evofem生物科學警報:Evofem生物科學公司股價下跌22.0%
該公司市值為758萬美元,本益比為-0.03,貝塔係數為-1.51。該業務的50日簡單移動均線切入位為0.73美元,200日簡單移動均線切入位為3.29美元。
依沃費姆生物科學公司(納斯達克代碼:EVFM-GET Rating)最近一次發佈財報是在5月10日(星期二)。這家生物技術公司公佈了該季度每股收益(2.88美元),比分析師普遍預期的(2.99美元)高出0.11美元。該公司本季度營收為425萬美元,而市場普遍預期為413萬美元。賣方分析師預計,Evofem Biosciences,Inc.本年度每股收益將達到2.72歐元。內部人士下注
在相關新聞中,首席執行官Saundra L.Pelletier在5月27日星期五的交易中收購了Evofem Biosciences的14.1萬股票。這些股票是以每股0.35美元的平均價格購買的,總交易額為49,350.00美元。交易完成後,首席執行官現在直接擁有公司236,722股,價值約82,852.70美元。這筆交易是在提交給美國證券交易委員會的一份檔案中披露的,可以通過這個超鏈接訪問該檔案。3.90%的股份由公司內部人士持有。
機構投資者參與Evofem生物科學
機構投資者和對沖基金最近調整了對該股的持有量。道富集團在第一季度將其在Evofem Biosciences的股票頭寸提高了4.5%。道富集團目前持有393,070股這家生物技術公司的股票,價值13.4萬美元,此前該公司在上個季度又購買了17,021股。GSA Capital Partners LLP在第四季度將其在Evofem Biosciences的頭寸增加了1431.6%。GSA Capital Partners LLP在上個季度額外購買了864,400股票後,現在擁有924,781股這家生物技術公司的股票,價值347,000美元。最後,Mirador Capital Partners LP在第一季度將其在Evofem Biosciences的頭寸增加了3408.9%。Mirador Capital Partners LP現在擁有這家生物技術公司2,807,681股股票,價值955,000美元,此前在上個季度又購買了2,727,664股。機構投資者持有該公司12.92%的股票。
Evofem生物科學公司簡介
(獲取評級)
Evofem Biosciences,Inc.是一家生物製藥公司,開發和銷售各種產品,以解決女性在性健康和生殖健康方面未得到滿足的需求。它的商業產品是Phexxi,一種用於避孕的陰道凝膠。該公司還參與了EVO100的開發,這是一種抗菌陰道凝膠,用於預防女性沙眼衣原體感染和淋球菌感染的泌尿生殖道傳播。
進一步閱讀
- 免費獲取StockNews.com關於Evofem生物科學的研究報告(EVFM)
- 3M、霍尼韋爾、通用電氣在季度報告後收購嗎?
- 這只國防股票的基本面和技術面都看漲
- 索菲金融股票終於準備好為投資者買單了嗎?
- CVS和Walgreens展示為什麼投資目標很重要
- 美敦力和直覺外科公司準備實現大增長嗎?
接受《Evofem生物科學日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Evofem Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧